0001415889-24-013656.txt : 20240517
0001415889-24-013656.hdr.sgml : 20240517
20240517215757
ACCESSION NUMBER: 0001415889-24-013656
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240515
FILED AS OF DATE: 20240517
DATE AS OF CHANGE: 20240517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jones Erin
CENTRAL INDEX KEY: 0001754278
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38663
FILM NUMBER: 24962216
MAIL ADDRESS:
STREET 1: C/O GRITSTONE ONCOLOGY, INC.
STREET 2: 5858 HORTON STREET, SUITE 210
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gritstone bio, Inc.
CENTRAL INDEX KEY: 0001656634
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 300
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 871-6100
MAIL ADDRESS:
STREET 1: 5959 HORTON STREET, SUITE 300
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: Gritstone Oncology, Inc.
DATE OF NAME CHANGE: 20151023
4
1
form4-05182024_010550.xml
X0508
4
2024-05-15
0001656634
Gritstone bio, Inc.
GRTS
0001754278
Jones Erin
C/O GRITSTONE BIO, INC.
5959 HORTON STREET, SUITE 300
EMERYVILLE
CA
94608
false
true
false
false
EVP, CHIEF OPERATING OFFICER
0
Common Stock
2024-05-15
4
A
0
27128
0
A
373042
D
Common Stock
2024-05-16
4
S
0
13749
0.7483
D
359293
D
Stock Option (Right to Buy)
0.75
2024-05-15
4
A
0
235000
0
A
2034-05-14
Common Stock
235000
235000
D
Represents Performance Stock Units ("PSUs") granted on March 22, 2024 that were earned by the Reporting Person as a result of the achievement of certain performance criteria as certified by the Issuer's Board of Directors on May 15, 2024. The PSUs vest over one year; 1/2 vested on May 15, 2024, and thereafter the remaining 1/2 will vest on May 15, 2025, subject to the continuing service of the Reporting Person on such vesting date. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock.
Includes 362,735 Restricted Stock Units ("RSUs") and PSUs which are subject to vesting.
The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of PSUs.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.735 to $0.7616 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the
staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vests as to 1/2 of the total grant on September 30, 2024, with the remainder of grant vesting on September 30, 2025, subject to the continued service of the Reporting Person on each vesting date.
/s/ Vassiliki Economides, Attorney-in-Fact for Erin Jones
2024-05-17